
Please try another search
(Reuters) -Axsome Therapeutics Inc said on Monday the U.S. Food and Drug Administration did not ask for additional information on the company's drug to treat depression as the agency continues to review it, sending shares of the drug developer surging 44% before the bell.
The regulator had set an action date of Aug. 22 to decide on the drug, but notified Axsome earlier this month of some deficiencies with its marketing application that could lead to a delay in deciding the fate of the oral pill.
Analysts had expected the FDA to decline Axsome's application, with Truist Securities analyst Joon Lee saying the lack of a "complete response letter" from the FDA was positive as it implied previously identified deficiencies can be remedied.
Shares in Axsome are down 74% this year through Friday's close.
AXS-05 had succeeded in reducing symptoms of major depressive disorder (MDD) in a late-stage trial in December 2019 and also showed benefits for treatment-resistant patients in a mid-stage study in 2020.
Depression affects about 16 million American adults every year, and existing antidepressants including Eli Lilly (NYSE:LLY)'s Prozac and Pfizer Inc (NYSE:PFE)'s Zoloft are designed to increase the availability of a mood-regulating neurotransmitter called serotonin.
But a large number of patients do not respond to those therapies, which could take up to six weeks to show any effect. Companies are developing new drugs that target the treatment-resistant population, which could reach 2.5 million in the United States by 2025, according to SMBC Nikko Securities America analyst David Hoang.
Axsome's AXS-05 targets several neurotransmitters including serotonin and is designed to reduce symptoms of depression in one week.
Rival Sage Therapeutics in June reported data from its late-stage study showing its drug candidate, zuranolone, improved symptoms of depression, but there were concerns about durability.
By Huw Jones LONDON (Reuters) - Global shares edged higher on Thursday as investors bet on the pace of interest rate hikes slowing after data pointed to inflation peaking, leaving...
By John Revill ZURICH (Reuters) -Siemens said on Thursday it continued to see strong industrial demand during its third quarter, as costs related to its Siemens Energy investment...
By Victoria Waldersee BERLIN (Reuters) -Daimler Truck will keep prices high even if certain costs begin to fall in order to compensate for lower margins since last year, the...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.